Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

Abstract Background Incretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. Tirzepatide (TZP), a dual GIP/GLP1-receptor agon...

Full description

Saved in:
Bibliographic Details
Main Authors: Zsombor I. Hegedűs, Márk E. Jakab, Tamás G. Gergely, Nabil V. Sayour, Andrea Kovács, Sára Antal, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga, Viktória E. Tóth
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Cardiovascular Diabetology
Subjects:
Incretin analogues
Heart failure
Tirzepatide
Liraglutide
HFrEF
Online Access:https://doi.org/10.1186/s12933-025-02806-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items